Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNITI-Jr phase 3 ustekinumab study in pediatric Crohn's disease
MOH_2023-01-09_012271Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in Crohn's disease (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Not reported. Started Dec 2022; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2023-01-09_012271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-09_012271.